https://www.bioworld.com/rss en-us Total med-tech financing through the first half (H1) of 2026 reached $12.66 billion, down from 2025’s $17.56 billion but in line with 2024’s $13.94 billion over the same period. http://www.bioworld.com/articles/733046 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733046-med-tech-financing-slows-in-q2-as-follow-ons-lead-a-mixed-first-half Financial line graph Global drug approvals through the first half (H1) of 2026 reached 261, the third-highest H1 total in BioWorld’s records behind 2021’s 288 and 2025's 271, and ahead of 2022’s 256. June was the standout month of the first six months at 64 approvals, the highest single month in BioWorld’s records and a notable acceleration from May’s 43. BioWorld’s records behind 2021’s 288 and 2025's 271, and ahead of 2022’s 256. June was the standout month of the first six months at 64 approvals, the highest single month in BioWorld’s records and a notable acceleration from May’s 43.]]> http://www.bioworld.com/articles/733045 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733045-june-sets-single-month-record-as-global-approvals-log-third-best-h1 Approved stamp Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to international partnerships, licensing, clinical development and a bigger role in the global biomedical ecosystem. http://www.bioworld.com/articles/733044 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733044-taiwan-biotech-looks-outward-in-next-phase-of-growth Lee-Cheng Liu, chairman, Taiwan BIO Lee-Cheng Liu, chairman, Taiwan BIO New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria. http://www.bioworld.com/articles/733043 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733043-apac-roundup-nmpa-nods-lupins-16m-spinoff-car-t-data-more Globe isolated on white background with focus on Asia and Australia Kolon Tissuegene Inc.’s TG-C, an allogeneic cell and gene therapy candidate for knee osteoarthritis (OA), missed both co-primary endpoints and all key secondary endpoints in a highly anticipated top-line phase III clinical trial readout. http://www.bioworld.com/articles/733042 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733042-kolon-tissuegene-shares-fall-as-tg-c-misses-knee-oa-endpoints 3D illustration of knee joint Otsuka Pharmaceutical Co. Ltd. will likely look next to expand the label of Simtriyo (centanafadine) into patients with comorbid anxiety, having won the U.S. FDA’s green light as a once-daily extended-release capsule for attention deficit hyperactivity disorder (ADHD) in adults plus pediatrics age 6 years and older who weigh at least 20 kg (about 44 lbs.). http://www.bioworld.com/articles/733041 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733041-otsukas-simtriyo-nod-qelbree-vs-three-in-adhd Tangled lines above silhouette Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Abelzeta, Astrazeneca, Daiichi Sankyo, Haisco, JCR, Junshi, Kyowa Kirin, Nuvectis, Seegene. http://www.bioworld.com/articles/732850 Tue, 28 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732850-regulatory-actions-for-july-28-2026 Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Ashlins, Clinuvel, Eleo, Elephas, Evogene, Forge Biologics, Hebei Senlang, Invitrocue, Lee’s, Kaveri, Lupin, Polypeptide Group, Restore Vision, Samsung Biologics, Tempest. http://www.bioworld.com/articles/732849 Tue, 28 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732849-other-news-to-note-for-july-28-2026 Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Actinogen, D&D Pharmatech, Harrow, Radiopharm Theranostics, Samsung Bioepis, Summit, Suzhou Ribo. http://www.bioworld.com/articles/732848 Tue, 28 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732848-in-the-clinic-for-july-28-2026 Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Rege Nephro, Tikva Allocell. http://www.bioworld.com/articles/732847 Tue, 28 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732847-financings-for-july-28-2026 BioWorld Asia briefs for July 28, 2026 http://www.bioworld.com/articles/435994 Tue, 28 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/435994-news-in-brief Axiom Biosciences, rebranded from Cytonus Therapeutics Inc. in June 2026, plans to be one of the first U.S. biotechs to IPO on the main board of The Stock Exchange of Hong Kong. The San Diego-based company is preparing audits as the first step to a potential IPO in 2027. http://www.bioworld.com/articles/732752 Tue, 21 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732752-us-based-axiom-plans-hong-kong-listing HKEX exterior Credit: Lewis Tse Pui Lung - stock.adobe.com Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion. BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion.]]> http://www.bioworld.com/articles/732845 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732845-junes-257b-m-and-a-haul-caps-biopharmas-record-breaking-first-half Chess board and pieces, blocks spelling out M&A Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd. and its EGFR inhibitor for lung cancer, as well as Innovent Biologics Inc. and its anti-CD40L antibody for a chronic fibroinflammatory condition. http://www.bioworld.com/articles/732844 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732844-asia-deal-flurry-draws-az-spero-to-1b-dizal-innovent-assets Global deals illustration Hansoh Pharmaceutical Group Co. Ltd. has taken a new step in the evolution of China’s “newco” strategy, combining its newly created U.S. company, Avere Therapeutics Inc., with Nasdaq-listed Nextcure Inc. in a deal designed less to merge pipelines than to create a public vehicle for global development of a China-originated asset. http://www.bioworld.com/articles/732843 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732843-hansoh-takes-newco-route-to-globalize-il-23-asset Glass globe with documents and pen Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization. http://www.bioworld.com/articles/732842 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732842-capital-remains-selective-in-barbell-biotech-market International currency symbols Advancell Co. Ltd. has raised an oversubscribed $315 million series D round to accelerate its push to become a fully integrated global radiopharma developer, funding late-stage clinical development alongside isotope supply and manufacturing infrastructure. http://www.bioworld.com/articles/732841 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732841-advancell-raises-315m-to-power-global-isotope-strategy Philina Lee, CEO, Advancell Advancell CEO Philina Lee (left). Credit: Advancell Co. Ltd. The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution. http://www.bioworld.com/articles/732840 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732840-to-viral-or-not-to-viral-in-vivo-car-t-debates-delivery-tech Red CAR T cell on blue blackground Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Aspen Pharmacare, Bioarctic, Clinuvel, Eisai, Orasis, Shionogi, Sichuan Biokin, Systimmune. http://www.bioworld.com/articles/732777 Tue, 21 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732777-regulatory-actions-for-july-21-2026 Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Adneuris, Bioarctic, China Medical System, Dimerix, DP Technology, Eisai, Excalipoint, Insilico Medicine, Mission, Organon, Samsung Bioepis, Zheijiang Conba. http://www.bioworld.com/articles/732776 Tue, 21 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732776-other-news-to-note-for-july-21-2026 Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Axiom, Eisai, Immutep, Innocare, Kelun-Biotech, Medinno, Merck, Takeda. http://www.bioworld.com/articles/732775 Tue, 21 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732775-in-the-clinic-for-july-21-2026 Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Advancell, Senhwa. http://www.bioworld.com/articles/732774 Tue, 21 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732774-financings-for-july-21-2026 New hires and promotions in the biopharma and med-tech industries in Asia-Pacific, including: Adlai Nortye. http://www.bioworld.com/articles/732773 Tue, 21 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732773-appointments-and-advancements-for-july-21-2026 Island Pharmaceuticals Ltd. has secured government and ethics approvals to deploy its investigational antiviral galidesivir in patients infected during the escalating Bundibugyo Ebola outbreak in Africa, giving the small Australian biotech a rare opportunity to collect prospective human data in an active filovirus emergency. http://www.bioworld.com/articles/732671 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732671-island-pharma-targets-ebola-species-lacking-approved-treatments Ebola virus For decades, treatment options for osteoarthritis have followed a familiar path: As cartilage deteriorates and pain worsens, conservative therapies eventually give way to joint replacement surgery. Australian regenerative medicine company Integrant Pty Ltd. wants to change that trajectory. Rather than replacing damaged joints, the Sydney-based company is building a platform designed to regenerate cartilage and preserve joint function by combining biologics, medical devices and artificial intelligence. http://www.bioworld.com/articles/732670 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732670-integrant-targets-cartilage-repair-with-ai-biologics-platform Illustration of leg anatomy with target around knee Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody mezagitamab (TAK-079) is showing benefits beyond platelet restoration, with new data suggesting the candidate may improve quality of life for patients with chronic immune thrombocytopenia (ITP) and sustain those gains after treatment ends. http://www.bioworld.com/articles/732669 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732669-takedas-mezagitamab-adds-quality-of-life-gains-to-itp-responses Antibodies and red blood cells South Korea is moving ahead with its biggest reform of drug review and pricing in more than a decade, reflecting a wider shift across Asian markets to reward innovation and tighten controls on generics. http://www.bioworld.com/articles/732668 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732668-korea-targets-generics-innovation-in-drug-pricing-overhaul Generic drugs and bottle Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China. http://www.bioworld.com/articles/732667 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732667-chinas-mindrank-raises-52m-series-b-to-advance-oral-glp-1 Blue digital dollar sign The U.S. FDA declined to approve, for a third time, an investigational liver cancer drug regimen comprising HLB Co. Ltd.’s rivoceranib and Jiangsu Hengrui Pharmaceutical Co. Ltd.’s camrelizumab, reportedly citing issues from a drug manufacturing facility inspection. http://www.bioworld.com/articles/732666 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732666-hlb-hengrui-receive-third-us-fda-rejection-on-liver-cancer-combo Liver tumor treatment conceptual illustration Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. http://www.bioworld.com/articles/732665 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732665-astrazeneca-nabs-pde3-4-inhibitor-for-copd-in-21b-sino-deal Red lungs on blue background